Pharma, Pharmaceutics and Biotechnology Conference

Epigenetic drugs are the most revolutionary approach in the treatment of modern medicine, by targeting mechanisms that control gene expression without altering the underlying DNA sequence.

This session will include health and disease, development of epigenetic therapy, and their potential applications toward the treatment of most diseases, especially cancer.

Understanding Epigenetics Epigenetic modifications are heritable, meaning changes that affect gene expression but do not alter the DNA sequence. Mechanisms of epigenetic regulation include DNA methylation, histone modification, and non-coding RNA interactions.

Attendees will be exposed to how such epigenetic alterations impact cellular function and form the basis for disease pathogenesis, a phenomenon very illustrative in cancer, neurological disorders, and metabolic diseases. Epigenetic

drug mechanisms: Mechanisms of drugs include the reversal of aberrant epigenetic alterations so normal gene expression can be restored. A block of lectures will focus on the types of drugs-which include: DNA methyltransferase inhibitors, such as azacitidine and gemcitabine; and histone deacetylase inhibitors, among them vorinostat and romidepsin.

Such drugs, as part of their mechanism of action, inhibit specific therapeutic targets. Therapeutic Applications the therapeutic applications of drugs based on epigenetics are gigantic, particularly in oncology.

This session will be dedicated to clinical studies that established the efficacy of epigenetic therapy in various cancers. From hematological malignancies to solid tumors. Discussions will also be undertaken concerning a combination of epigenetic drugs with the conventional therapies for better treatment outcomes or to overcome drug resistance.

Development challenges: Although the prospect of epigenetic drugs is very bright, several challenges emerge in their development. Among these challenges are specificity issues and off-target effects and after effects of modifying epigenetic marks for the long term.

This session will identify challenges and the strategies currently being adopted in the pharmaceutical industry to mitigate risk and to improve therapeutic utility of epigenetic drugs. Future Directions: While epigenetic research progresses, so do new therapeutic strategies.

The participants will learn of the future directions in epigenetic drug development including integration of epigenetic therapies with approaches from precision medicine, but also possibly the first steps into the use of epigenetic modulation for the treatment of non-cancerous diseases.

By the end of this session, participants will take away an integrated appreciation for epigenetic drugs within contemporary therapeutics and the transformative promise they hold for diseases.

Learn about these revolutionary advancements in epigenetic therapies and their potential to change the face of future medicine.